Core Viewpoint - Kintara Therapeutics is urging stockholders to vote on proposals necessary for the completion of its merger with TuHURA Biosciences, emphasizing the importance of stockholder approval for the future of the company [1][2][4]. Group 1: Merger Details - The proposed merger with TuHURA requires a "FOR" vote on Proposals 3 & 5 from a majority of Kintara's voting power as of August 14, 2024 [1][2]. - Proposal 3 seeks approval to amend Kintara's Articles of Incorporation to increase the number of authorized shares [4]. - Proposal 5 involves the reincorporation of Kintara from Nevada to Delaware, along with a plan of conversion [5]. Group 2: Voting Information - Stockholders must cast their votes by 11:59 p.m. ET on September 19, 2024, to ensure their votes count [1][6]. - Voting can be done via phone or internet, with specific instructions provided for different platforms [5][6]. Group 3: Company Background - Kintara Therapeutics focuses on developing new therapies for solid tumors, with its lead program being REM-001 Therapy for cutaneous metastatic breast cancer [9][10]. - The company has a proprietary photodynamic therapy platform that has shown an 80% clinical efficacy in previous trials [10]. Group 4: TuHURA Biosciences Overview - TuHURA is an immuno-oncology company in Phase 3 development, working on technologies to overcome resistance to cancer immunotherapy [7]. - Its lead product candidate, IFx-2.0, aims to enhance the effectiveness of existing treatments like Keytruda® for advanced Merkel Cell Carcinoma [7][8].
Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences